Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19


Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202.

Bednasz CJ, Venuto CS, Ma Q, Daar ES, Sax PE, Fischl MA, Collier AC, Smith KY, Tierney C, Acosta EP, Mager DE, Morse GD; AIDS Clinical Trials Group Study A5202 Team.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e01638-18. doi: 10.1128/AAC.01638-18. Print 2019 Apr.


Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s.

Venuto CS, Lim J, Messing S, Hunt PW, McComsey GA, Morse GD.

Antivir Ther. 2018;23(4):345-351. doi: 10.3851/IMP3209.


Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants.

Bednasz CJ, Venuto CS, Ma Q, Daar ES, Sax PE, Fischl MA, Collier AC, Smith KY, Tierney C, Yang Y, Wilding GE, Morse GD.

Ther Drug Monit. 2017 Dec;39(6):596-603. doi: 10.1097/FTD.0000000000000443.


Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation.

Latourelle JC, Beste MT, Hadzi TC, Miller RE, Oppenheim JN, Valko MP, Wuest DM, Church BW, Khalil IG, Hayete B, Venuto CS.

Lancet Neurol. 2017 Nov;16(11):908-916. doi: 10.1016/S1474-4422(17)30328-9. Epub 2017 Sep 25.


Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s.

Gupta SK, Yeh E, Kitch DW, Brown TT, Venuto CS, Morse GD, Ha B, Melbourne K, McComsey GA.

J Antimicrob Chemother. 2017 Jul 1;72(7):2042-2048. doi: 10.1093/jac/dkx076.


Paritaprevir and Ritonavir Liver Concentrations in Rats as Assessed by Different Liver Sampling Techniques.

Venuto CS, Markatou M, Woolwine-Cunningham Y, Furlage R, Ocque AJ, DiFrancesco R, Dumas EO, Wallace PK, Morse GD, Talal AH.

Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02283-16. doi: 10.1128/AAC.02283-16. Print 2017 May.


Pharmacokinetic Considerations for Combining Antiretroviral Therapy, Direct-Acting Antiviral Agents for Hepatitis C Virus, and Addiction Treatment Medications.

Bednasz CJ, Venuto CS, Ma Q, Morse GD.

Clin Pharmacol Drug Dev. 2017 Mar;6(2):135-139. doi: 10.1002/cpdd.313. Review.


Assessment of Hepatic Impairment and Implications for Pharmacokinetics of Substance Use Treatment.

Talal AH, Venuto CS, Younis I.

Clin Pharmacol Drug Dev. 2017 Mar;6(2):206-212. doi: 10.1002/cpdd.336. Review.


Intrahepatic Sampling for the Elucidation of Antiviral Clinical Pharmacology.

Venuto CS, Talal AH.

Clin Pharmacol Drug Dev. 2017 Mar;6(2):169-175. doi: 10.1002/cpdd.311.


A review of disease progression models of Parkinson's disease and applications in clinical trials.

Venuto CS, Potter NB, Dorsey ER, Kieburtz K.

Mov Disord. 2016 Jul;31(7):947-956. doi: 10.1002/mds.26644. Epub 2016 May 26. Review.


Recent advances in management of the HIV/HCV coinfected patient.

Bednasz CJ, Sawyer JR, Martinez A, Rose PG, Sithole SS, Hamilton HR, Kaufman FS, Venuto CS, Ma Q, Talal A, Morse GD.

Future Virol. 2015;10(8):981-997.


Lipid-Lowering Therapy in HIV-Infected Patients: Relationship with Antiretroviral Agents and Impact of Substance-Related Disorders.

Bednasz C, Luque AE, Zingman BS, Fischl MA, Gripshover BM, Venuto CS, Gu J, Feng Z, DiFrancesco R, Morse GD, Ma Q.

Curr Vasc Pharmacol. 2016;14(3):280-7.


Effect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation.

Rowe IA, Tully DC, Armstrong MJ, Parker R, Guo K, Barton D, Morse GD, Venuto CS, Ogilvie CB, Hedegaard DL, McKelvy JF, Wong-Staal F, Allen TM, Balfe P, McKeating JA, Mutimer DJ.

Liver Transpl. 2016 Mar;22(3):287-97. doi: 10.1002/lt.24349.


Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202.

Venuto CS, Mollan K, Ma Q, Daar ES, Sax PE, Fischl M, Collier AC, Smith KY, Tierney C, Morse GD.

J Antimicrob Chemother. 2014 Dec;69(12):3300-10. doi: 10.1093/jac/dku303. Epub 2014 Aug 25.


Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine.

Smith KY, Tierney C, Mollan K, Venuto CS, Budhathoki C, Ma Q, Morse GD, Sax P, Katzenstein D, Godfrey C, Fischl M, Daar ES, Collier AC; AIDS Clinical Trials Group 5202 Study Team.

Clin Infect Dis. 2014 Feb;58(4):555-63. doi: 10.1093/cid/cit747. Epub 2013 Nov 18.


Pharmacologic approaches to the treatment of Huntington's disease.

Venuto CS, McGarry A, Ma Q, Kieburtz K.

Mov Disord. 2012 Jan;27(1):31-41. doi: 10.1002/mds.23953. Epub 2011 Oct 13. Review.


Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders.

Ma Q, Zingman BS, Luque AE, Fischl MA, Gripshover BM, Venuto CS, DiFrancesco R, Forrest A, Morse GD.

Ther Drug Monit. 2011 Jun;33(3):309-14. doi: 10.1097/FTD.0b013e31821d3adb.


Advocacy Recruiting for Huntington's Disease Clinical Trials.

Goodman L, Sia C, Carnes R, Vetter L, Taubman F, Venuto CS, McGarry A, Kieburtz K, Agarwal P.

PLoS Curr. 2011 Apr 12;3:RRN1230. doi: 10.1371/currents.RRN1230.


Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV.

Ma Q, Brazeau D, Zingman BS, Reichman RC, Fischl MA, Gripshover BM, Venuto CS, Slish JC, DiFrancesco R, Forrest A, Morse GD.

Pharmacogenomics. 2007 Mar;8(3):227-35.


Supplemental Content

Loading ...
Support Center